Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Piedad Reche"'
Autor:
Alfonso Yubero, Purificación Estévez, Aránzazu Barquín, Luisa Sánchez, Ana Santaballa, Bella Pajares, Piedad Reche, Carmen Salvador, Luis Manso, Raúl Márquez, Antonio González-Martín
Publikováno v:
Gynecologic Oncology Reports, Vol 48, Iss , Pp 101211- (2023)
The poly(ADP-ribose) polymerase inhibitor (PARPi) rucaparib is approved as maintenance therapy for patients with platinum-sensitive recurrent high-grade ovarian cancer (HGOC). The efficacy and safety of rucaparib after PARPi therapy are largely unkno
Externí odkaz:
https://doaj.org/article/cc16796a046e48fda32bbd7c694a6f16
Autor:
Alfonso Yubero, Aranzazu Barquín, Purificación Estévez, Bella Pajares, Luisa Sánchez, Piedad Reche, Jesús Alarcón, Julia Calzas, Lydia Gaba, José Fuentes, Ana Santaballa, Carmen Salvador, Luis Manso, Ana Herrero, Álvaro Taus, Raúl Márquez, Julia Madani, María Merino, Gloria Marquina, Victoria Casado, Manuel Constenla, María Gutiérrez, Alba Dosil, Antonio González-Martín
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access
Externí odkaz:
https://doaj.org/article/535064772afa48388b62acdd5418de2a
Autor:
Alfonso Yubero, Aranzazu Barquín, Lydia Gaba, Bella Pajares, Piedad Reche, Carmen Salvador, Jesús Alarcón, Luis Manso, Raúl Marquez, Jose Fuentes, Julia Madani, Manuel Costenla, Maria Gutierrez-Toribio, Purificacion Estevez-García, Ana Santaballa, Luisa Sanchez-Lorenzo, Julia Calzas, Ana Herrero, Alvaro Taus, Antonio Gonzalez-Martin
Publikováno v:
Ovarian cancer.
Autor:
Alfonso Yubero-Esteban, Piedad Reche-Molina, Carmen Salvador Coloma, Purificación Estévez-García, Luis Manso, Marcos Iglesias Campos, Arantzazu Barquin, Raul Marquez, Ana Santaballa, Julia Calzas, Ana Herrero, Victoria Casado, Julia Madani, Maria Merino, Gloria Marquina, Jesus Alarcon Company, Lydia Gaba, Jose Fuentes Pradera, Antonio Gonzalez Martin, Maria Luisa Sanchez Lorenzo
Publikováno v:
Journal of Clinical Oncology. 40:e17598-e17598
e17598 Background: Rucaparib is a PARP inhibitor (PARPi) approved as maintenance therapy for platinum (Pt)-sensitive recurrent high-grade ovarian cancer (HGOC), and as treatment for BRCA-mutant HGOC patients. To date, there is little evidence about t
Autor:
Alfonso Yubero-Esteban, Arantzazu Barquin, Lydia Gaba, Marcos Iglesias Campos, Piedad Reche-Molina, Carmen Salvador Coloma, Jesus Alarcon Company, Luis Manso, Raul Marquez, Jose Fuentes Pradera, Julia Madani, Manuel Constenla Figueiras, Maria Gutierrez-Toribio, Purificación Estévez-García, Ana Santaballa, Maria Luisa Sanchez Lorenzo, Julia Calzas, Ana Herrero, Alvaro Taus, Antonio Gonzalez Martin
Publikováno v:
Journal of Clinical Oncology. 40:e17562-e17562
e17562 Background: Rucaparib is a PARP inhibitor approved for the treatment of high-grade ovarian cancer (HGOC). Clinical trials have demonstrated its benefit both as maintenance therapy (MTN) for platinum (Pt)-sensitive recurrent HGOC, and as treatm